Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.52 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.52 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.33 |
| ▸ | MVD | P53602 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17307945 | 0.89 | LPAR3 (0.42) | LPAR3LPAR2LPAR1LPAR5MVD | |
| SCHEMBL3241679 | 0.88 | LPAR3 (0.64) | LPAR3LPAR2LPAR1LPAR5CSNK2A2 | |
| SCHEMBL4526743 | 0.88 | LPAR3 (0.64) | LPAR3LPAR2LPAR1LPAR5CSNK2A2 | |
| SCHEMBL4521589 | 0.88 | LPAR3 (0.64) | LPAR3LPAR2LPAR1LPAR5CSNK2A2 | |
| SCHEMBL2370053 | 0.88 | LPAR3 (0.64) | LPAR3LPAR2LPAR1LPAR5CSNK2A2 | |
| SCHEMBL4532022 | 0.88 | LPAR3 (0.64) | LPAR3LPAR2LPAR1LPAR5CSNK2A2 | |
| SCHEMBL4528918 | 0.88 | LPAR3 (0.64) | LPAR3LPAR2LPAR1LPAR5CSNK2A2 | |
| SCHEMBL4528254 | 0.88 | LPAR3 (0.64) | LPAR3LPAR2LPAR1LPAR5CSNK2A2 | |
| SCHEMBL4536604 | 0.88 | LPAR3 (0.64) | LPAR3LPAR2LPAR1LPAR5CSNK2A2 | |
| SCHEMBL4529198 | 0.88 | LPAR3 (0.64) | LPAR3LPAR2LPAR1LPAR5CSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257745-A1 | Circular siRNAs | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| EP-4223299-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-3705125-B1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11666653-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220143189-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-05-12 | — | — | US | disclosed |
| US-20220008541-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2022-01-13 | — | — | US | disclosed |
| US-10844375-B2 | Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkers | TRANSLATE BIO MA, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-10806791-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190184018-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | BANK OF AMERICA, N.A. | 2019-06-20 | — | — | US | disclosed |
| US-20180326070-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. | 2018-11-15 | — | — | US | disclosed |
| US-20130178512-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC (US) | 2013-07-11 | — | — | US | disclosed |
| US-8450467-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120136042-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC (US) | 2012-05-31 | — | — | US | disclosed |
| WO-2012037254-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20110118340-A1 | DELIVERY OF RNAI CONSTRUCTS TO OLIGODENDROCYTES | ALNYLAM PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| EP-2231194-A2 | FOLATE-IRNA CONJUGATES | Alnylam Pharmaceuticals Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| EP-2229186-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | Alnylam Pharmaceuticals Inc. (US) | 2010-09-22 | — | — | EP | disclosed |
| US-20090239814-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| WO-2009082606-A2 | FOLATE CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| WO-2009073809-A2 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118340-A1 | DELIVERY OF RNAI CONSTRUCTS TO OLIGODENDROCYTES | AS3MT, NSUN2, FBL | LPAR3 990/4885LPAR2 589/4885LPAR1 1001/4885 |
| US-20180326070-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | LPXN, ZYX, OSTC | LPAR3 381/4885LPAR2 386/4885LPAR1 327/4885 |
| US-20130178512-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | LPXN, ZYX, OSTC | LPAR3 381/4885LPAR2 386/4885LPAR1 327/4885 |
| US-20190184018-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | SLC2A2, SLC2A8, SLC2A1 | LPAR3 973/4885LPAR2 934/4885LPAR1 1445/4885 |
| US-11666653-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | HAVCR2, B3GAT3, CSGALNACT1 | LPAR3 272/4885LPAR2 536/4885LPAR1 409/4885 |
| US-20220008541-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | SLC2A2, SLC2A8, SLC2A1 | LPAR3 973/4885LPAR2 934/4885LPAR1 1445/4885 |
| US-20220143189-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | HAVCR2, B3GAT3, CSGALNACT1 | LPAR3 272/4885LPAR2 536/4885LPAR1 409/4885 |
| US-20090239814-A1 | Carbohydrate Conjugates as Delivery Agents for Oligonucleotides | LPXN, ZYX, OSTC | LPAR3 381/4885LPAR2 386/4885LPAR1 327/4885 |
| US-10806791-B2 | Carbohydrate conjugates as delivery agents for oligonucleotides | SLC2A2, SLC2A8, SLC2A1 | LPAR3 973/4885LPAR2 934/4885LPAR1 1445/4885 |
| US-20120136042-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | LPXN, ZYX, OSTC | LPAR3 381/4885LPAR2 386/4885LPAR1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.